Despite a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about the longevity of the company and has resorted to cutting preclinical programs and evaluating strategic options.

Adaptimmune Therapeutics announces 33% workforce reduction and restructuring to save $300 million through 2028. Company halts uza-cel ovarian cancer trial while maintaining Galapagos collaboration. Fo...

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $6.55 million for the quarter. Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) last announced its quarterly earnings […]

→ Megan McGill has replaced David Lucchino as CEO of Brenig Therapeutics, an OrbiMed-backed neuro biotech that collected a $65 million Series A ...

YouTube video by Hisseseven

Die US-amerikanische Roche-Tochter Genentech hat eine strategische Zusammenarbeit mit der an der amerikanischen Technologiebörse Nasdaq notierten Adaptimmune Therapeutics beendet. Dabei ging es um die...

Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP – Free Report) – Equities research analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for Adaptimmune Therapeutics in a research report issued to clients and investors on Tuesday, July 29th. HC Wainwright analyst A. He now forecasts that the biotechnology company will post earnings per share of […]

After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans to offer jobs to about half of the biotech’s employees. | After months of ...

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes to the Company's Board of Directors ("Board") and its Executive Leadership team, which are effective from November 14, 2025.Christopher (Chris) Hill, currently Chief Financial Officer ("CFO") of the Company, has been appointed as Chief Executive Officer ("CEO") and a Director of the Company,...

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Company's Board of Directors (the "Board") has determined to initiate the delisting of its American Depositary Shares ("ADSs"), each representing six ordinary shares, from The Nasdaq Capital Market ("Nasdaq") and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the...